The northeastern part of the United States is approaching the annual
respiratory syncytial virus (RSV) season, which is November 2014 through March
2015. RSV is the most common cause of bronchiolitis and pneumonia among
children younger than one year old. During RSV season AmeriHealth will approve
the monthly administration of Synagis® (palivizumab) for
children in accordance with the 2014-2015 recommendations from the American
Academy of Pediatrics (AAP).
It is mandatory for all participating providers to obtain
Synagis® (palivizumab) through ACRO Pharmaceutical Services, an
independent company. AmeriHealth will coordinate with ACRO Pharmaceutical
Services to facilitate delivery of Synagis® (palivizumab) to
your office.
If you have questions about the Synagis® (palivizumab)
distribution program, please contact Customer Service at
1-800-275-2583 for providers in Pennsylvania and Delaware or
at 1-888-YOUR-AH1 (1-888-968-7241) for providers in New
Jersey. The October edition of Partners in Health UpdateSM
will include detailed information about how to order Synagis®
(palivizumab), as well as the complete list of 2014-2015 recommendations for
Synagis® (palivizumab) from the AAP.
Learn more
Review Medical Policy #08.00.22l: Immune Prophylaxis for Respiratory
Syncytial Virus to learn more. Visit our
Medical Policy Portal, select Accept and Go to Medical
Policy Online, and type the policy name or number in the Search box.
Note: MedImmune, LLC, the maker of Synagis
®
(palivizumab), has a voluntary program called RSV Connection
TM;
however, AmeriHealth does not participate in this program.
This is not a statement of benefits. Benefits may vary
according to state requirements, product line (HMO, PPO, etc.), and/or employer
groups. Member coverage can be verified by calling Customer Service at
1-800-275-2583 for providers in Pennsylvania and Delaware or
at 1-888-YOUR-AH1 (1-888-968-7241) for providers in New
Jersey. .